Osteotropic therapy via targeted layer-by-layer nanoparticles

Stephen W Morton1, Nisarg J Shah, Mohiuddin A Quadir

  • 1The David H. Koch Institute for Integrative Cancer Research, Department of Chemical Engineering Institute for Soldier Nanotechnologies 77 Massachusetts Avenue, Cambridge, MA, 02139.

Insights

Developing targeted drug carriers using Layer-by-Layer assembly shows promise for treating osteosarcoma. This novel approach enhances drug delivery to tumors, improving efficacy and reducing side effects for bone cancer patients.

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Oncology

Background:

  • Current treatments for bone diseases like osteosarcoma are often ineffective.
  • There is a critical need for targeted therapies to improve treatment efficacy and minimize side effects.

Purpose of the Study:

  • To develop functional and targeted drug carriers for primary osteosarcoma treatment.
  • To utilize Layer-by-Layer (LbL) assembly for creating tissue-specific drug delivery systems.

Main Methods:

  • Surface modification of drug-loaded nanoparticles using poly(acrylic acid) (PAA) functionalized with alendronate.
  • In vitro testing of nanoparticle binding and internalization in osteosarcoma cells.
  • In vivo efficacy studies using LbL-targeted doxorubicin liposomes in mouse models.

Main Results:

  • PAA-alendronate coated nanoparticles demonstrated rapid binding and internalization in osteosarcoma cells.
  • LbL-targeted doxorubicin liposomes showed potent in vitro toxicity.
  • In vivo studies confirmed enhanced and prolonged tumor accumulation, leading to significantly improved therapeutic efficacy.

Conclusions:

  • LbL assembly offers a tunable approach for synthesizing targeted drug carriers.
  • Surface modification of nanoparticles with alendronate enables effective tissue-specific targeting for osteosarcoma.
  • This strategy holds potential for improving systemic drug delivery and treatment outcomes for bone cancers.